156 related articles for article (PubMed ID: 37090874)
1. Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single-center experience of eight patients.
Liu Z; Xiao Y; Xu J; Liu M; Han M; Hu W; Zhu D
Laryngoscope Investig Otolaryngol; 2023 Apr; 8(2):435-440. PubMed ID: 37090874
[TBL] [Abstract][Full Text] [Related]
2. Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.
Collette F; Lawson G; Hassid S; Delahaut G; Bachy V; Van Der Vorst S; Faugeras L; Gilliaux Q; D'Hondt L
Head Neck; 2023 May; 45(5):1071-1079. PubMed ID: 36840929
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Follow-Up on Systemic Bevacizumab Treatment in Recurrent Respiratory Papillomatosis.
Evers G; Schliemann C; Beule A; Schmidt LH; Schulze AB; Kessler C; Hoffmann TK; Wiewrodt R; Groll AH; Bleckmann A; Rudack C; Berdel WE; Mohr M
Laryngoscope; 2021 Jun; 131(6):E1926-E1933. PubMed ID: 33382105
[TBL] [Abstract][Full Text] [Related]
4. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey.
Best SR; Mohr M; Zur KB
Laryngoscope; 2017 Oct; 127(10):2225-2229. PubMed ID: 28657692
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.
So RJ; Hidalgo Lopez JC; Ballestas SA; Klein AM; Steuer C; Shin DM; Abousaud M; Teng Y; Saba NF; Tkaczuk AT; Schaefer ES; Seiwert TY; McClellan K; Best SR
Laryngoscope; 2024 Feb; 134(2):577-581. PubMed ID: 37470254
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis.
Ballestas SA; Hidalgo Lopez J; Klein AM; Steuer C; Shin DM; Abousaud M; Schmitt NC; Teng Y; Saba NF; Tkaczuk AT
Laryngoscope; 2023 Oct; 133(10):2725-2733. PubMed ID: 36815602
[TBL] [Abstract][Full Text] [Related]
7. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.
So RJ; Rayle C; Joo HH; Huang EY; Seiwert TY; Raabe EH; Best SR
Laryngoscope; 2024 Jul; 134(7):3253-3259. PubMed ID: 38525973
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review.
Pogoda L; Ziylan F; Smeeing DPJ; Dikkers FG; Rinkel RNPM
Eur Arch Otorhinolaryngol; 2022 Sep; 279(9):4229-4240. PubMed ID: 35462578
[TBL] [Abstract][Full Text] [Related]
9. Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population.
Tkaczuk A; Trivedi S; Mody MD; Steuer CE; Shin DM; Klein AM; Saba NF
Laryngoscope; 2021 Mar; 131(3):E921-E928. PubMed ID: 33107615
[TBL] [Abstract][Full Text] [Related]
10. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review.
Enrique OH; Eloy SH; Adrian TP; Perla V
Am J Otolaryngol; 2021; 42(5):103126. PubMed ID: 34175693
[TBL] [Abstract][Full Text] [Related]
11. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis.
Mohr M; Schliemann C; Biermann C; Schmidt LH; Kessler T; Schmidt J; Wiebe K; Müller KM; Hoffmann TK; Groll AH; Werner C; Kessler C; Wiewrodt R; Rudack C; Berdel WE
Oncol Lett; 2014 Nov; 8(5):1912-1918. PubMed ID: 25289079
[TBL] [Abstract][Full Text] [Related]
12. Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up.
Ruiz R; Balamuth N; Javia LR; Zur KB
Laryngoscope; 2022 Oct; 132(10):2071-2075. PubMed ID: 35043981
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of bevacizumab and cidofovir treatment in HPV-associated recurrent respiratory papillomatosis - review of the literature.
Jackowska J; Piersiala K; Klimza H; Wierzbicka M
Otolaryngol Pol; 2018 Jun; 72(4):1-8. PubMed ID: 30190442
[TBL] [Abstract][Full Text] [Related]
14. Recurrent respiratory papillomatosis: A 2020 perspective.
Benedict JJ; Derkay CS
Laryngoscope Investig Otolaryngol; 2021 Apr; 6(2):340-345. PubMed ID: 33869767
[TBL] [Abstract][Full Text] [Related]
15. Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis.
Tatineni S; Warren Z; Applebaum MA; Baroody FM
Case Rep Oncol Med; 2022; 2022():2767996. PubMed ID: 36483909
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of respiratory papillomatosis--a case report on systemic treatment with bevacizumab].
Nagel S; Busch C; Blankenburg T; Schütte W
Pneumologie; 2009 Jul; 63(7):387-9. PubMed ID: 19591084
[TBL] [Abstract][Full Text] [Related]
17. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.
Bedoya A; Glisinski K; Clarke J; Lind RN; Buckley CE; Shofer S
Am J Case Rep; 2017 Jul; 18():842-846. PubMed ID: 28757601
[TBL] [Abstract][Full Text] [Related]
18. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children.
Rogers DJ; Ojha S; Maurer R; Hartnick CJ
JAMA Otolaryngol Head Neck Surg; 2013 May; 139(5):496-501. PubMed ID: 23681032
[TBL] [Abstract][Full Text] [Related]
19. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population.
Wiatrak BJ; Wiatrak DW; Broker TR; Lewis L
Laryngoscope; 2004 Nov; 114(11 Pt 2 Suppl 104):1-23. PubMed ID: 15514560
[TBL] [Abstract][Full Text] [Related]
20. Experience with Systemic Bevacizumab in Advanced Juvenile Recurrent Respiratory Papillomatosis.
Aggarwal K; Kumar R; Kumari J; Kumar A; Jat KR; Kabra SK; Bhalla AS; Kumar R
Indian J Otolaryngol Head Neck Surg; 2022 Dec; 74(Suppl 3):5117-5121. PubMed ID: 36742877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
